This FDA approval adds a significant growth driver to AZN's oncology pipeline. Monitor initial prescription trends and EU regulatory decision as near-term catalysts. The 67% Grade 3+ adverse event rate warrants attention for real-world adoption but does not diminish the clinical differentiation as the only targeted therapy in this biomarker-defined population.
AZN drugs
AZN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 15 $177.27entry
- T+1 · 5mo ago +0.78%α +1.35% · $178.65
- T+5 · 5mo ago −0.47%α +0.91% · $176.43
- T+20 · 4mo ago −4.40%α −3.65% · $169.47
- T+60 · 2mo ago −11.47%α −12.47% · $156.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca announced FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone as the first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer. The approval is based on the CAPItello-281 Phase III trial showing a 19% reduction in risk of radiographic progression or death and a 7.5-month improvement in median rPFS versus standard of care. This expands Truqap into a second tumor type with a large addressable US patient population of approximately 35,000 annually, one in four of whom have PTEN-deficient tumors.
Key Facts
- FDA approved Truqap combination as first and only targeted treatment for PTEN-deficient mAPMN/S prostate cancer
- CAPItello-281 trial showed 19% risk reduction in radiographic progression or death (HR 0.81; p=0.034)
- Median rPFS improved by 7.5 months (33.2 vs 25.7 months) versus abiraterone + ADT alone
- Approximately 35,000 US patients diagnosed annually with mAPMN/S prostate cancer; ~25% have PTEN-deficient tumors
- Companion diagnostic for PTEN deficiency also approved concurrently
- EU regulatory application under review based on same trial
Financial Impact
Expands Truqap's addressable market into a second oncology indication with ~35,000 US patients annually; peak sales potential not disclosed but represents a meaningful new revenue stream for AstraZeneca's oncology portfolio
Risk Factors
- OS data immature; final survival readout could alter risk-benefit profile
- 67% Grade 3+ adverse event rate may limit real-world adoption versus existing therapies
- Competition from other PI3K/AKT pathway inhibitors and emerging prostate cancer treatments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005964 |
| Document: 0001654954-26-005964-index-headers.html | 0001654954-26-005964 |
| Document: 0001654954-26-005964-index.html | 0001654954-26-005964 |
| Document: 0001654954-26-005964.txt | 0001654954-26-005964 |
Track record
77 reports on AZN
19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers